This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MaassenVanDenBrink, A. Articles by Saxena, P. R. Search for Related Content PubMed PubMed Citation Articles by MaassenVanDenBrink, A. Articles by Saxena, P. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ERGOTAMINE METHYSERGIDE Medline Plus Health Information Headache Migraine

(Circulation. 1998;98:25-30.)
© 1998 American Heart Association, Inc.

Clinical Investigation and Reports

Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs

Antoinette MaassenVanDenBrink, MSc; Marije Reekers, MSc; Willem A. Bax, MD, PhD; Michel D. Ferrari, MD, PhD; ; Pramod R. Saxena, MD, PhD

From the Department of Pharmacology, Erasmus University Rotterdam, and Department of Neurology (M.D.F.), Leiden University Medical Centre, the Netherlands. Dr Bax is now with the Department of Cardiology and Internal Medicine, Eemland Hospital, Amersfoort, the Netherlands.

Correspondence to P.R. Saxena, MD, PhD, Department of Pharmacology, Erasmus University Rotterdam, Dr Molewaterplein 50, PO Box 1738, 3000 DR Rotterdam, Netherlands. E-mail saxena{at}farma.fgg.eur.nl

Background—The antimigraine drugs ergotamine and sumatriptan may cause angina-like symptoms, possibly resulting from coronary artery constriction. We compared the coronary vasoconstrictor potential of a number of current and prospective antimigraine drugs (ergotamine, dihydroergotamine, methysergide and its metabolite methylergometrine, sumatriptan, naratriptan, zolmitriptan, rizatriptan, avitriptan).

Methods and Results—Concentration-response curves to the antimigraine drugs were constructed in human isolated coronary artery segments to obtain the maximum contractile response (E_max) and the concentration eliciting 50% of E_max (EC₅₀). The EC₅₀ values were related to maximum plasma concentrations (C_max) reported in patients, obtaining C_max/EC₅₀ ratios as an index of coronary vasoconstriction occurring in the clinical setting. Furthermore, we studied the duration of contractile responses after washout of the acutely acting antimigraine drugs to assess their disappearance from the receptor biophase. Compared with sumatriptan, all drugs were more potent (lower EC₅₀ values) in contracting the coronary artery but had similar efficacies (E_max <25% of K⁺-induced contraction). The C_max of avitriptan was 7- to 11-fold higher than its EC₅₀ value, whereas those of the other drugs were <40% of their respective EC₅₀ values. The contractile responses to ergotamine and dihydroergotamine persisted even after repeated washings, but those to the other drugs declined rapidly after washing.

Conclusions—All current and prospective antimigraine drugs contract the human coronary artery in vitro, but in view of low efficacy, these drugs are unlikely to cause myocardial ischemia at therapeutic plasma concentrations in healthy subjects. In patients with coronary artery disease, however, these drugs must remain contraindicated. The sustained contraction by ergotamine and dihydroergotamine seems to be an important disadvantage compared with sumatriptan-like drugs.

Key Words: coronary disease • vasoconstriction • migraine • pharmacology • antimigraine drugs

This article has been cited by other articles:

				C. P. Regan, G. L. Stump, S. A. Kane, and J. J. Lynch Jr. Calcitonin Gene-Related Peptide Receptor Antagonism Does Not Affect the Severity of Myocardial Ischemia during Atrial Pacing in Dogs with Coronary Artery Stenosis J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 571 - 578. [Abstract] [Full Text] [PDF]

				A. Bhattacharya, K. W. Schenck, Y.-C. Xu, L. Nisenbaum, E. Galbreath, and M. L. Cohen 5-Hydroxytryptamine1B Receptor-Mediated Contraction of Rabbit Saphenous Vein and Basilar Artery: Role of Vascular Endothelium J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 825 - 832. [Abstract] [Full Text] [PDF]

				S. J. Tepper, A. M. Rapoport, and F. D. Sheftell Mechanisms of Action of the 5-HT1B/1D Receptor Agonists Arch Neurol, July 1, 2002; 59(7): 1084 - 1088. [Abstract] [Full Text] [PDF]

				P. P. A. Humphrey, W. Fenvik, R. Salonen, P. R. Saxena, R. W. M. van den Broek, and A. MaassenVanDenBrink Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels Neurology, July 10, 2001; 57(1): 162 - 163. [Full Text] [PDF]

				E. L. H. Spierings, B. Gomez-Mancilla, D. E. Grosz, C. R. Rowland, F. S. Whaley, and K. J. Jirgens Oral Almotriptan vs Oral Sumatriptan in the Abortive Treatment of Migraine: A Double-blind, Randomized, Parallel-Group, Optimum-Dose Comparison Arch Neurol, June 1, 2001; 58(6): 944 - 950. [Abstract] [Full Text] [PDF]

				A. M. VanDenBrink, R. W. M. van den Broek, R. de Vries, A. J. J. C. Bogers, C. J. J. Avezaat, and P. R. Saxena Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels Neurology, November 28, 2000; 55(10): 1524 - 1530. [Abstract] [Full Text] [PDF]

				T. Gnecchi-Ruscone, X. Bernard, P. Pierre, D. Anderson, N. Legg, H. Enahoro, P. D. O. Winter, A. Crisp, J. A. Melin, and P. G. Camici Effect of naratriptan on myocardial blood flow and coronary vasodilator reserve in migraineurs Neurology, July 12, 2000; 55(1): 95 - 99. [Abstract] [Full Text] [PDF]

				A. Bahra, M. J. Gawel, J.-E. Hardebo, D. Millson, S. A. Breen, and P. J. Goadsby Oral zolmitriptan is effective in the acute treatment of cluster headache Neurology, May 9, 2000; 54(9): 1832 - 1839. [Abstract] [Full Text] [PDF]

				P. Tfelt-Hansen, P. R. Saxena, C. Dahlof, J. Pascual, M. Lainez, P. Henry, H.-C. Diener, J. Schoenen, M. D. Ferrari, and P. J. Goadsby Ergotamine in the acute treatment of migraine: A review and European consensus Brain, January 1, 2000; 123(1): 9 - 18. [Abstract] [Full Text] [PDF]

				A. MaassenVanDenBrink, R. de Vries, P. R. Saxena, M. A.D.H. Schalekamp, and A.H.J. Danser Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase Cardiovasc Res, November 1, 1999; 44(2): 407 - 415. [Abstract] [Full Text] [PDF]

				G. W. John, P. J. Pauwels, M. Perez, S. Halazy, B. Le Grand, Y. Verscheure, J.-P. Valentin, C. Palmier, T. Wurch, P. Chopin, et al. F 11356, a Novel 5-Hydroxytryptamine (5-HT) Derivative with Potent, Selective, and Unique High Intrinsic Activity at 5-HT1B/1D Receptors in Models Relevant to Migraine J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 83 - 95. [Abstract] [Full Text]

				Coronary Vasoconstriction with Antimigraine Drugs Journal Watch (General), July 24, 1998; 1998(724): 5 - 5. [Full Text]